M
Matthew P. Goetz
Researcher at Mayo Clinic
Publications - 366
Citations - 20018
Matthew P. Goetz is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 53, co-authored 283 publications receiving 15406 citations. Previous affiliations of Matthew P. Goetz include University of Rochester.
Papers
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,Della F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,Matthew P. Goetz,John A. Olson,John A. Olson,Tracy Lively,Sunil Badve,Thomas J. Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Soonmyung Paik,William C. Wood,Peter M. Ravdin,Maccon M. Keane,Henry L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,Jeffery L. Berenberg,Jeffrey Abrams,George W. Sledge +31 more
TL;DR: In this paper, the authors performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer.
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch-Shimon,Jens Huober,In Hae Park,Olivier Tredan,Shin-Cheh Chen,Luis Manso,Orit Freedman,Georgina Garnica Jaliffe,T. Forrester,Martin Frenzel,Susana Barriga,Ian C. Smith,Nawel Bourayou,Angelo Di Leo +17 more
TL;DR: Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Journal ArticleDOI
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
Matthew P. Goetz,James M. Rae,Vera J. Suman,Stephanie L. Safgren,Matthew M. Ames,Daniel W. Visscher,Carol Reynolds,Fergus J. Couch,Wilma L. Lingle,David A. Flockhart,Zeruesenay Desta,Edith A. Perez,James N. Ingle +12 more
TL;DR: In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with the previous observation that CYP3A5*3 variant was not associated with any of these clinical outcomes.